A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., Chen, H., Li, H., Huang, H., Tu, S., Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z., Zhang, Y., Li, H., Shang, L., Wang, K., Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., Zou, J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., Jaki, T., Hayden, F., Horby, P., Zhang, D. & Wang, C. (2020). A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2001282
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19